Company intelligence / Profile preview
Angimmune LLC
Rockville, Maryland, United Statesangimmune.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Angimmune has conducted a Phase 2 multi-center randomized clinical trial evaluating the effectiveness of a single four-day treatment with Resimmune compared to oral Zolinza in patients with stage IB/IIB mycosis fungoides. Their divalent Anti-CD3 biologic has shown 2+ year anti-tumor effects in CTCL after a single cycle.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- ImmunotoxinsFusion proteinAnti-T cell immunotoxinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Scott & White Healthcare
Beyond the preview
Go deeper on Angimmune LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angimmune LLC.